FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer
Status:
Withdrawn
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Neoadjuvant 5-Fu based chemoradiation followed by surgery is a standard treatment for locally
advanced rectal cancer. However, radiation-related side effects could not be neglected. But
this multimodality strategy failed to improve survival. Neoadjuvant chemotherapy alone may be
an alternative strategy to minimize treatment-related toxicities without compromising the
oncology outcome. Thus, patients with MRI-defined CRM-positive rectal cancer will receive 6
cycles of neoadjuvant treatment with FOLFOXIRI followed by surgery. The purpose of the study
is to evaluate the efficacy of FOLFOXIRI alone as neoadjuvant treatment in treating patients
with locally advanced rectal cancer.